CN110582490A - 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法 - Google Patents

抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法 Download PDF

Info

Publication number
CN110582490A
CN110582490A CN201880024426.7A CN201880024426A CN110582490A CN 110582490 A CN110582490 A CN 110582490A CN 201880024426 A CN201880024426 A CN 201880024426A CN 110582490 A CN110582490 A CN 110582490A
Authority
CN
China
Prior art keywords
cancer
parpi
sra737
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880024426.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·哈西格
B·W·斯特劳斯
R·J·汉森
K·L·安德雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sierra Oncology Inc
Original Assignee
Sierra Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sierra Oncology Inc filed Critical Sierra Oncology Inc
Priority to CN202311004815.2A priority Critical patent/CN116999564A/zh
Publication of CN110582490A publication Critical patent/CN110582490A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880024426.7A 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法 Pending CN110582490A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311004815.2A CN116999564A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762483888P 2017-04-10 2017-04-10
US62/483,888 2017-04-10
US201762552364P 2017-08-30 2017-08-30
US62/552,364 2017-08-30
US201862614268P 2018-01-05 2018-01-05
US62/614,268 2018-01-05
US201862635394P 2018-02-26 2018-02-26
US62/635,394 2018-02-26
US201862650185P 2018-03-29 2018-03-29
US62/650,185 2018-03-29
PCT/US2018/026917 WO2018191277A1 (en) 2017-04-10 2018-04-10 Chk1 (sra737)/parpi combination methods of inhibiting tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311004815.2A Division CN116999564A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法

Publications (1)

Publication Number Publication Date
CN110582490A true CN110582490A (zh) 2019-12-17

Family

ID=63793688

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880024426.7A Pending CN110582490A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法
CN202311004815.2A Pending CN116999564A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311004815.2A Pending CN116999564A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法

Country Status (9)

Country Link
US (1) US11596637B2 (https=)
EP (1) EP3609884A4 (https=)
JP (1) JP7273791B2 (https=)
KR (1) KR102645511B1 (https=)
CN (2) CN110582490A (https=)
AU (2) AU2018250552B2 (https=)
CA (1) CA3059576A1 (https=)
MX (1) MX2019012176A (https=)
WO (1) WO2018191277A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3065803A1 (en) * 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies
CA3092079A1 (en) * 2018-02-26 2019-08-29 Sierra Oncology, Inc. Methods of treatment of cancer comprising chk1 inhibitors
WO2020198510A1 (en) * 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
US20220226338A1 (en) * 2019-05-14 2022-07-21 Sierra Oncology, Inc. Methods of Treating Cancer Using CHK1 Inhibitors
KR102285996B1 (ko) * 2019-08-08 2021-08-05 차의과학대학교 산학협력단 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도
EP4087563A4 (en) * 2020-01-07 2024-03-27 Shanghai Huayu Biotechnology Co., Ltd. COMBINATION CANCER THERAPY WITH CHK INHIBITOR
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
AU2021325905A1 (en) 2020-08-12 2023-04-13 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer
KR20230146593A (ko) * 2021-02-16 2023-10-19 리본 테라퓨틱스 인코포레이티드 Parp7 억제제에 대한 투여량 레지멘

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
CN101743003A (zh) * 2007-05-25 2010-06-16 阿斯利康(瑞典)有限公司 用于治疗癌症的chk和parp抑制剂的组合
WO2012074754A1 (en) * 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CN104302635A (zh) * 2012-05-15 2015-01-21 癌症研究技术有限公司 5-[[4-[[吗啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈及其治疗应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2009099601A2 (en) 2008-02-04 2009-08-13 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
GB201316526D0 (en) 2013-09-17 2013-10-30 King S College London Biomarkers
WO2015077602A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating and monitoring cancers
WO2018191299A1 (en) 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
CA3065803A1 (en) 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies
CA3092079A1 (en) 2018-02-26 2019-08-29 Sierra Oncology, Inc. Methods of treatment of cancer comprising chk1 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
CN101743003A (zh) * 2007-05-25 2010-06-16 阿斯利康(瑞典)有限公司 用于治疗癌症的chk和parp抑制剂的组合
WO2012074754A1 (en) * 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
CN104302635A (zh) * 2012-05-15 2015-01-21 癌症研究技术有限公司 5-[[4-[[吗啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈及其治疗应用
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINT MITCHELL等: "Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells", 《MOL PHARMACOL.》 *
ELIZABETH H. STOVER等: "Biomarkers of Response and Resistance to DNA Repair Targeted Therapies", 《CLIN CANCER RES》 *
HYOUNG KIM等: "Targeting theATR/CHK1Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models", 《CLINICAL CANCER RESEARCH》 *
LAURENCE BOOTH等: "PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells", 《CANCER BIOLOGY & THERAPY》 *
YEVGENIY KIM等: "Reverse the Resistance to PARP Inhibitors", 《INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES》 *

Also Published As

Publication number Publication date
CN116999564A (zh) 2023-11-07
JP7273791B2 (ja) 2023-05-15
US11596637B2 (en) 2023-03-07
MX2019012176A (es) 2020-02-19
KR20200009004A (ko) 2020-01-29
JP2020516693A (ja) 2020-06-11
EP3609884A4 (en) 2021-01-06
EP3609884A1 (en) 2020-02-19
AU2022259818A1 (en) 2022-12-01
US20210077499A1 (en) 2021-03-18
AU2018250552A1 (en) 2019-11-14
AU2018250552B2 (en) 2022-08-04
WO2018191277A1 (en) 2018-10-18
CA3059576A1 (en) 2018-10-18
KR102645511B1 (ko) 2024-03-08

Similar Documents

Publication Publication Date Title
US11596637B2 (en) CHK1 (SRA737)/PARPi combination methods of inhibiting tumor growth
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
KR20180118229A (ko) 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
Konstantinopoulos et al. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
AU2019350581B2 (en) Methods of treatment of cancer comprising Cdc7 inhibitors
Leung et al. Poly (ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality
Ganguly et al. Role of biomarkers in the development of PARP inhibitors
Singh et al. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR-ErbB2 signaling with lapatinib
US20200157638A1 (en) Biomarkers and patient selection strategies
JP2024012649A (ja) Ｃｈｋ１阻害剤を含む癌の治療方法
Baker et al. Radiation and chemo-sensitizing effects of DNA-PK inhibitors are proportional in tumors and normal tissues
JP2016512812A (ja) バイオマーカー
CN114072526A (zh) 使用chk1抑制剂治疗癌症的方法
Tenzer et al. Signal transduction inhibitors as radiosensitizers
Zhao et al. Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia cell lines by inhibiting the P13K/AKT signaling pathway
Gupta et al. Understanding cytotoxicity induction by plumbagin in pancreatic ductal adenocarcinoma using network pharmacology, bioinformatic and in-vitro study
Yao et al. Jatrorrhizine Exhibits an Antitumor Effect Against Gefitinib‐resistant Non‐small Cell Lung Cancer via Inhibiting PI3K/mTOR Phosphorylation
Przystal et al. DDRE-03. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS
Marquardt Preclinical evaluation of HDAC inhibitors for epigenetic therapy of primary brain tumors
Gewirtz Treatment-Induced Autophagy Associated with Tumor Dormancy and Relapse

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20191217

RJ01 Rejection of invention patent application after publication